cardiology
(11)
Evolent
The company betting that the most expensive corner of American medicine - cancer, cardiology, and back surgery - can be run better when the people paying for care and the doctors delivering it are finally pulling in the same direction.
Axon Therapies, Inc.
Axon Therapies is a clinical-stage medical device company developing SAVM (Splanchnic Ablation for Volume Management), a minimally invasive, implant-free catheter procedure that ablates the greater splanchnic nerve to calm an overactive sympathetic nervous system and rebalance blood volume in patients with heart failure - particularly heart failure with preserved ejection fraction (HFpEF). Incubated by the medtech studio Coridea and backed by leading healthcare investors, the company is advancing its Satera Ablation System through randomized, sham-controlled feasibility trials.
Heartflow
Heartflow is a Silicon Valley medical technology company that uses AI and computational fluid dynamics to turn a standard coronary CT scan into a personalized, color-coded 3D model of a patient's heart. Its FFRCT, Plaque and RoadMap analyses help cardiologists diagnose and manage coronary artery disease non-invasively, reducing the need for invasive angiograms. Founded in 2007 and headquartered in San Francisco, Heartflow has analyzed hundreds of thousands of patients across more than 1,500 U.S. hospitals and went public on the Nasdaq (HTFL) in August 2025.
Revamp Medical
Revamp Medical is an Israeli medical device company building the Doraya catheter, a temporary, adjustable flow-reducing catheter for patients hospitalized with acute heart failure. Deployed in the infrarenal inferior vena cava for up to 12 hours, Doraya is designed to relieve venous congestion and improve response to diuretic therapy in patients who respond poorly to standard drugs - addressing the local mechanism of diuretic resistance rather than relying on systemic drugs or dialysis. Founded in 2016 and based in Netanya, the company won FDA Breakthrough Device designation in 2020 and closed a KCK Medtech-led Series A in 2023 to fund U.S. clinical trials.
HelpWear
HelpWear is a Toronto-based medical device company building the HeartWatch, a medical-grade ambulatory ECG monitor engineered for extended, continuous wear. Its signature dry-electrode, non-adhesive design avoids the skin irritation that limits traditional adhesive patch monitors, letting patients wear it comfortably for long stretches while it streams clinical-grade heart-rhythm data to physicians. The company targets hard-to-catch conditions like cryptogenic stroke, unexplained syncope and long-term arrhythmia detection, positioning the device as a tool to guide physician decisions and support telemedicine.
Karoo Health
Karoo Health is an Albuquerque, New Mexico company building tech-enabled, value-based cardiovascular care. It pairs wraparound care teams - nurses, dietitians, pharmacists, health coaches and advanced-practice providers - with Kohere.ai, a proprietary platform that aggregates patient data, flags risk and coordinates communication. The model helps cardiology networks, health systems and health plans move from fee-for-service to value-based arrangements, aiming to improve heart-patient outcomes while lowering the cost of care.
Wearlinq
Wearlinq is a San Francisco healthtech company building eWave, described as the first continuous, wireless, FDA 510(k)-cleared 6-lead ECG cardiac monitor. About the size of a coin and worn on a skin-like adhesive patch, eWave pairs with a patient's own smartphone, runs 5+ days between charges in an AirPods-style case, and streams near-real-time data so clinicians get hospital-grade multi-lead visibility without the bulk of a wired Holter monitor. The company also operates an IDTF (independent diagnostic testing facility) staffed by certified cardiographic technicians who turn around STAT reports, closing the loop from device to diagnosis.
AngioWave Imaging
AngioWave Imaging is a Massachusetts-based medical AI company building post-processing software that sharpens fluoroscopic angiograms in the cardiac catheterization lab. Its FDA 510(k)-cleared AngioWaveNet uses a spatiotemporal, convolutional deep neural network (branded STEP) to reveal blood-vessel detail that is hard to see on the raw angiogram, helping interventional cardiologists diagnose and treat coronary artery disease. The software runs on top of any existing fluoroscopy system, requiring no new hardware.
Auxilius Pharma
Auxilius Pharma is a clinical-stage cardiovascular pharmaceutical company developing AUX-001, a once-daily extended-release formulation of nicorandil for the roughly 11 million Americans living with chronic stable angina. By reformulating an established molecule through the FDA's 505(b)(2) pathway, the company aims to deliver what would be the first new innovative oral angina therapy in the US since 2006 - improving adherence, tolerability and outcomes for patients who still suffer symptoms despite optimal treatment.
Procyrion, Inc.
Procyrion, Inc. is a Houston-based medical device company developing Aortix, a catheter-delivered percutaneous mechanical circulatory support (pMCS) pump. About the width of a pencil, Aortix is anchored in the descending aorta where it unloads the failing heart while boosting blood flow to the kidneys, targeting acute decompensated heart failure and cardiorenal syndrome. The device holds FDA Breakthrough Device Designation and is in the DRAIN-HF pivotal IDE trial after closing a $57.7M Series E in February 2024.
Tempus AI
Tempus AI is a Chicago-based health technology company that has built one of the world's largest libraries of clinical and molecular data, paired with an AI operating system that helps physicians and researchers make data-driven decisions in oncology, cardiology, radiology, and beyond. Founded in 2015 by Groupon co-founder Eric Lefkofsky after his wife's cancer diagnosis, the company sequences patient genomes, structures messy clinical records, and turns that data into diagnostics and AI tools used across a majority of U.S. academic medical centers. It went public on Nasdaq in June 2024 under the ticker TEM.